Treatment of transgenic (TRAMP)-C2 murine PC models with a triple therapy (IL-15, anti-CTLA-4 and anti-PD-L1 antibodies) enhanced the CD8 + T cell cytotoxic activity and the antigen-specific IFN-γ release, inhibiting the suppressive functions of CD4+/CD25+ and CD8+/CD122+ Tregs [153]. The gene discussed is IFNG; the disease is pachyonychia congenita.